I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst Whitney Ijem maintained a Hold rating on Vertex Pharmaceuticals today and set a price target of $442.00. Ijem covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alnylam Pharma, and BioMarin Pharmaceutical. According to TipRanks, Ijem has an average return of 18.9% and a 47.29% success rate on recommended stocks. In addition to Canaccord Genuity, Vertex Pharmaceuticals also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued yesterday. However, today, Barclays maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
Canaccord Genuity analyst Whitney Ijem maintained a Hold rating on Vertex Pharmaceuticals today and set a price target of $442.00.
Ijem covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alnylam Pharma, and BioMarin Pharmaceutical. According to TipRanks, Ijem has an average return of 18.9% and a 47.29% success rate on recommended stocks.
In addition to Canaccord Genuity, Vertex Pharmaceuticals also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued yesterday. However, today, Barclays maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX).